1
|
Gupta S, Kashyap M, Bansal Y, Bansal G. In silico insights into design of novel VEGFR-2 inhibitors: SMILES-based QSAR modelling, and docking studies on substituted benzo-fused heteronuclear derivatives. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2024; 35:265-284. [PMID: 38591137 DOI: 10.1080/1062936x.2024.2332203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 03/14/2024] [Indexed: 04/10/2024]
Abstract
Eight QSAR models (M1-M8) were developed from a dataset of 118 benzo-fused heteronuclear derivatives targeting VEGFR-2 by Monte Carlo optimization method of CORALSEA 2023 software. Models were generated with hybrid optimal descriptors using both SMILES and Graphs with zero- and first-order Morgan extended connectivity index from a training set of 103 derivatives. All statistical parameters for model validation were within the prescribed limits, establishing the models to be robust and of excellent quality. Among all models, split-2 of M5 was the best-fit as reflected by r v a lidation 2 , Q v a lidation 2 and MAE . Mechanistic interpretation of this model assisted the identification of structural descriptors as promoters and hinderers for VEGFR-2 inhibition. These descriptors were utilized to design novel VEGFR-2 inhibitors (YS01-YS07) by bringing modifications in compound MS90 in the dataset. Docking of all designed compounds, MS90 and sorafenib with VEGFR-2 binding site revealed favourable binding interactions. Docking score of YS07 was higher than that of MS90 and sorafenib. Molecular dynamics simulation study revealed sustained interactions of YS07 with key amino acids of VEGFR-2 at a run time of 100 ns. This study concludes the development of a best fit QSAR model which can assist the design of new anticancer agents targeting VEGFR-2.
Collapse
Affiliation(s)
- S Gupta
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | - M Kashyap
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | - Y Bansal
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | - G Bansal
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| |
Collapse
|
2
|
Sun X, Xie Z, Lei X, Huang S, Tang G, Wang Z. Research and development of N, N'-diarylureas as anti-tumor agents. RSC Med Chem 2023; 14:1209-1226. [PMID: 37484562 PMCID: PMC10357950 DOI: 10.1039/d3md00053b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 05/08/2023] [Indexed: 07/25/2023] Open
Abstract
Tumor neovascularization provides abundant nutrients for the occurrence and development of tumors, and is also an important factor in tumor invasion and metastasis, which has attracted extensive attention in anti-tumor therapy. Sorafenib is a clinically approved multi-targeted anti-tumor drug that targets vascular endothelial growth factor receptor (VEGFR) and inhibits the formation of tumor angiogenesis, thereby achieving the purpose of suppressing tumor growth. Since the approval of sorafenib, N,N'-diarylureas have received extensive attention as the key pharmacophore in its chemical structure. And a series of N,N'-diarylureas were designed and synthesized to screen a new generation of anti-tumor drug candidates through chemical modification and structural optimization. Moreover, the rational design of targeted drugs is beneficial to reduce toxic side effects and drug resistance and improve the curative effect. Here, this article reviews the research progress in the design, classification, structure-activity relationship (SAR) and biological activity of N,N'-diarylureas, in order to provide some prospective routes for the development of clinically effective anti-tumor drugs.
Collapse
Affiliation(s)
- Xueyan Sun
- Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang Hunan 421001 China
| | - Zhizhong Xie
- Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang Hunan 421001 China
| | - Xiaoyong Lei
- Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang Hunan 421001 China
| | - Sheng Huang
- Jiuzhitang Co., Ltd Changsha Hunan 410007 China
| | - Guotao Tang
- Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang Hunan 421001 China
| | - Zhe Wang
- The Second Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China Hengyang 421001 Hunan China
| |
Collapse
|
3
|
Guzow K, Mulkiewicz E, Obuchowski M, Wiczk W. Biological activity of 3-(2-benzoxazol-5-yl)alanine derivatives. Amino Acids 2021; 53:1257-1268. [PMID: 34240252 PMCID: PMC8325670 DOI: 10.1007/s00726-021-03030-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 06/25/2021] [Indexed: 01/04/2023]
Abstract
Searching for new drugs is still a challenge for science, mainly because of civilization development and globalization which promote the rapid spread of diseases, which is particularly dangerous in the case of infectious ones. Moreover, readily available already known antibiotics are often overused or misused, possibly contributing to the increase in the number of multidrug-resistant microorganisms. A consequence of this is the need for new structures of potential drugs. One of them is a benzoxazole moiety, a basic skeleton of a group of fluorescent heterocyclic compounds already widely used in chemistry, industry, and medicine, which is also present in naturally occurring biologically active compounds. Moreover, synthetic benzoxazoles are also biologically active. Considering all of that, a large group of non-proteinogenic amino acids based on 3-(2-benzoxazol-5-yl)alanine skeleton was studied in search for new antimicrobial and anticancer agents. Screening tests revealed that antibacterial potential of 41 compounds studied is not very high; however, they are selective acting only against Gram-positive bacteria (B. subtilis). Moreover, almost half of the studied compounds have antifungal properties, also against pathogens (C. albicans). Most of studied compounds are toxic to both normal and cancer cells. However, in a few cases, toxicity to normal cells is much lower than for cancer cells indicating these compounds as future anticancer agents. The research carried out on such a large group of compounds allowed to establish a structure–activity relationship which enables to select candidates for further modifications, necessary to improve their biological activity and obtain a new lead structure with potential for therapeutic use.
Collapse
Affiliation(s)
- Katarzyna Guzow
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, Gdańsk, 80-308, Poland.
| | - Ewa Mulkiewicz
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, Gdańsk, 80-308, Poland
| | - Michał Obuchowski
- Laboratory of Molecular Bacteriology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Dębinki 1, Gdańsk, 80-211, Poland
| | - Wiesław Wiczk
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, Gdańsk, 80-308, Poland
| |
Collapse
|
4
|
Hou S, Liang S, Zhang C, Han Y, Liang J, Hu H, Zhang X, Hu C, Liu X, Zhang H. Design, Synthesis and Anticancer Activity of a New Series of N-aryl- N'-[4-(pyridin-2-ylmethoxy)benzyl]urea Derivatives. Molecules 2021; 26:molecules26123496. [PMID: 34201326 PMCID: PMC8226862 DOI: 10.3390/molecules26123496] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 05/26/2021] [Accepted: 05/29/2021] [Indexed: 01/22/2023] Open
Abstract
The development of cancer treatments requires continuous exploration and improvement, in which the discovery of new drugs for the treatment of cancer is still an important pathway. In this study, based on the molecular hybridization strategy, a new structural framework with an N-aryl-N'-arylmethylurea scaffold was designed, and 16 new target compounds were synthesized and evaluated for their antiproliferative activities against four different cancer cell lines A549, MCF7, HCT116, PC3, and human liver normal cell line HL7702. The results have shown seven compounds with 1-methylpiperidin-4-yl groups having excellent activities against all four cancer cell lines, and they exhibited scarcely any activities against HL7702. Among them, compound 9b and 9d showed greatly excellent activity against the four kinds of cells, and the IC50 for MCF7 and PC3 cell lines were even less than 3 μM.
Collapse
Affiliation(s)
- Shicheng Hou
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Shishao Liang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Chao Zhang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Yingmei Han
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Jianhui Liang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Hongyu Hu
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Xingeng Zhang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
| | - Chun Hu
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
- Correspondence: (C.H.); (X.L.); (H.Z.); Tel.: +86-24-43520246 (C.H.)
| | - Xiaoping Liu
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.H.); (S.L.); (C.Z.); (Y.H.); (J.L.); (H.H.); (X.Z.)
- Correspondence: (C.H.); (X.L.); (H.Z.); Tel.: +86-24-43520246 (C.H.)
| | - Hong Zhang
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
- Correspondence: (C.H.); (X.L.); (H.Z.); Tel.: +86-24-43520246 (C.H.)
| |
Collapse
|
5
|
Yan X, Wen J, Zhou L, Fan L, Wang X, Xu Z. Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity. Curr Top Med Chem 2020; 20:1916-1937. [PMID: 32579505 DOI: 10.2174/1568026620666200624161151] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 05/06/2020] [Accepted: 05/21/2020] [Indexed: 02/07/2023]
Abstract
Cancer, which has been cursed for human beings for long time is considered as one of the
leading causes of morbidity and mortality across the world. In spite of different types of treatments
available, chemotherapy is still deemed as a favored treatment for the cancer. Unfortunately, many currently
accessible anticancer agents have developed multidrug resistance along with fatal adverse effects.
Therefore, intensive efforts have been made to seek for new active drugs with improved anticancer efficacy
and reduced adverse effects. In recent years, the emergence of heterocyclic ring-containing anticancer
agents has gained a great deal of attention among medicinal chemists. 1,3- oxazole is a versatile
heterocyclic compound, and its derivatives possess broad-spectrum pharmacological properties, including
anticancer activity against both drug-susceptible, drug-resistant and even multidrug-resistant cancer
cell lines through multiple mechanisms. Thus, the 1,3-oxazole moiety is a useful template for the development
of novel anticancer agents. This review will provide a comprehensive overview of the recent
advances on 1,3-oxazole derivatives with potential therapeutic applications as anticancer agents, focus
on the chemical structures, anticancer activity, and mechanisms of action.
Collapse
Affiliation(s)
- Xinjia Yan
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Jing Wen
- College of Pharmacy, Harbin University of Commerce, Harbin, China
| | - Lin Zhou
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Lei Fan
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Xiaobo Wang
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Zhi Xu
- College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China
| |
Collapse
|